Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 44HER2-positive Breast Cancer 8Carcinoma, Non-Small-Cell Lung 5Breast Diseases 3Brain Neoplasms 3Advanced Breast Cancer 3Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Salivary Gland Neoplasms 1Rare Tumour 1Rare Tumor 1Pathologic Complete Response 1Non Small Cell Lung 1Neoplasm Metastasis 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1Metastatic Breast Cancer in the Brain 1Lung Neoplasms 1HER2-positive Metastatic Breast Cancer 1HER2-positive Early Breast Cancer 1HER2+ Early or Locally Advanced Breast Cancer 1HER2 Positive Metastatic Breast Cancer 1HER2 Positive Breast Cancer 1HER2 Insertion Mutation Positive Advanced NSCLC 1Estrogen Receptor-positive Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Digestive System Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Breast Cancer Invasive 1

Interventions

pyrotinib 1pertuzumab 1Trastuzumab 1Surgical Procedures, Operative 1Mastectomy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Cancer Invasive × pyrotinib × Clear all
NCT04398914 2022-03-31

Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Shanghai Jiao Tong University School of Medicine

Phase 2 Active not recruiting
216 enrolled
Breast

Breast Cancer Invasive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡